Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OBI PharmaROCO:4174 -1.24%45 PS Ratio is 62.70 as of Jul. 22, 2026, which is 92% below its 10-year median of 785.62. GuruFocus rates ROCO:4174 with a GF Score™ of 45/100 and a GF Value™ of NT$139.01 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 930 Biotechnology companies, OBI Pharma ranks worse than 81.29% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, OBI Pharma's share price is NT$27.90.
OBI Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.45. Hence, OBI Pharma's PS Ratio for today is 62.70.
Good Sign:
OBI Pharma Inc stock PS Ratio (=62.25) is close to 10-year low of 59.66.
The historical rank and industry rank for OBI Pharma's PS Ratio or its related term are showing as below:
ROCO:4174'
s PS Ratio Range Over the Past 10 Years
Min: 59.66 Med: 785.62 Max: 117534.99
Current: 62.7
During the past 13 years, OBI Pharma's highest PS Ratio was 117534.99. The lowest was 59.66. And the median was 785.62.
ROCO:4174's PS Ratio is ranked worse than 81.29% of 930
companies
in the Biotechnology industry
Industry Median: 9.205
vs ROCO:4174: 62.70
OBI Pharma Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of OBI Pharma was -6.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 119.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -2.20% per year.
During the past 13 years, OBI Pharma's highest 3-Year average Revenue per Share Growth Rate was 604.10% per year. The lowest was -62.20% per year. And the median was 7.30% per year.
Back to Basics: PS Ratio
OBI Pharma (ROCO:4174) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
OBI Pharma PS Ratio Related Terms
OBI Pharma PS Ratio Historical Data
* Premium members only.
The historical data trend for OBI Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4174 vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, OBI Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OBI Pharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OBI Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where OBI Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
OBI Pharma's Share Price of today is NT$27.90. OBI Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.45.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
OBI Pharma (ROCO:4174) has a PS Ratio of 62.70 as of Jul. 22, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on OBI Pharma and its competitors. This is 92% below median its historical median of 785.62. Over the past decade, OBI Pharma's PS Ratio has ranged from 59.66 to 117,534.99. According to the industry distribution chart, OBI Pharma ranks #756 out of 930 companies in the Biotechnology industry, placing it in the top 81.3%.
Is OBI Pharma's PS Ratio too high?
OBI Pharma's current PS Ratio of 62.70 is 92% below median its 10-year median of 785.62. Over the past 10 years, this metric has ranged from a low of 59.66 to a high of 117,534.99. The Biotechnology industry median PS Ratio is 9.21. OBI Pharma's value of 62.70 is 581.2% above this industry median. Based on the distribution chart, OBI Pharma ranks #756 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OBI Pharma has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OBI Pharma's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OBI Pharma ranks #756 out of 930 companies for PS Ratio. This places OBI Pharma in the lower half of its industry. The industry median PS Ratio is 9.21. OBI Pharma's value of 62.70 is 581.2% above this benchmark. Historically, OBI Pharma's own PS Ratio has ranged from 59.66 to 117,534.99 over the past decade. While the company's 10-year median is 785.62 vs. the industry median of 9.21, OBI Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.21, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OBI Pharma's current PS Ratio of 62.70 is 581.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on OBI Pharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OBI Pharma's current PS Ratio is 62.70, which is 92% below median its own 10-year median of 785.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OBI Pharma stock overvalued right now?
Based on GuruFocus' analysis, OBI Pharma (ROCO:4174) is currently considered Possible Value Trap. The stock's GF Value™ is NT$139.01, compared to a current price of NT$27.90 — trading 79.9% below its estimated fair value. The current PS Ratio is 62.70, which is 92% below median its 10-year median of 785.62 and 581.2% above the Biotechnology industry median of 9.21. OBI Pharma's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For OBI Pharma (ROCO:4174), the current PS Ratio is 62.70 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OBI Pharma (ROCO:4174) Overvalued in 2026?
Based on GuruFocus' analysis, OBI Pharma stock appears to be undervalued.
The current stock price of NT$27.90 is trading 79.9% below its estimated GF Value™ of NT$139.01.
GuruFocus considers OBI Pharma to be Possible Value Trap.
Key valuation signals for ROCO:4174:
PS Ratio: 62.70 (92% below median its 10-year median of 785.62)
GF Value™: NT$139.01 vs. price of NT$27.90 (79.9% below fair value)
Industry Position: 581.2% above the Biotechnology median (#756 of 930)
No single metric tells the full story. See the ROCO:4174 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OBI Pharma Inc is engaged in the research and development of novel therapeutic agents and biologics for patients with unmet medical needs. The company has three reportable segments: the anti-cancer new drug segment, the botulinum toxin new drug segment, and the CDMO segment. Geographically, it generates the majority of its revenue from Taiwan.
45GF Score
Get the complete analysis for ROCO:4174
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4174 has been successfully added to your 
